Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trialHelen M. Colhoun, John Fuller, D. J. Betteridge et al.|The Lancet|2004Cited by 3.8k
Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesA. Michael Lincoff, Donna H. Ryan, Kirstine Brown‐Frandsen et al.|New England Journal of Medicine|2023Cited by 2.6k
Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With StatinsS. Matthijs Boekholdt, John J.P. Kastelein, Benoît J. Arsenault et al.|JAMA|2012Cited by 800
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trialsJane Armitage, Martin Landray, Michael A. Blazing et al.|The Lancet|2019Cited by 785
High Risk of Cardiovascular Disease in Patients With Type 1 Diabetes in the U.K.Sabita S. Soedamah‐Muthu, Helen M. Colhoun, John Fuller et al.|Diabetes Care|2006Cited by 393